Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Ralfinamide: Phase IIb/III started

April 6, 2009 7:00 AM UTC

Newron began the 12-week, double-blind, international Phase IIb/III SERENA trial to compare 160 and 320 mg of oral ralfinamide given once daily vs. placebo in about 400 patients. Upon completion, pati...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article